in vivo News and Research

RSS

Scientists uncover new approach to develop induced pluripotent stem cells for in vivo disease modeling

In a paper in Cell Stem Cell, a team led by researchers in the Boston Children's Hospital's Stem Cell Transplantation Program reports a new approach for turning induced pluripotent stem cells (iPSCs) into hematopoietic stem and progenitor cells for in vivo disease modeling.

4 Oct 2013

Researchers develop new approach to combat tubercle bacillus

A new approach to combating the tubercle bacillus, the microorganism that kills some 1.5 million people in the world each year, has been developed by a French-British team including scientists from CNRS, Inserm, the Institut Curie and Université Toulouse III - Paul Sabatier.

2 Oct 2013

Scientists discover two new compounds that could help treat CF patients having common mutation

Cystic fibrosis is a lethal genetic disorder that in France affects one child per 4,500 births. An international team led by scientists at the Institut Fédératif de Recherche Necker-Enfants Malades (CNRS/Inserm/Université Paris Descartes), led by Aleksander Edelman, has recently discovered two new compounds that could be used to treat patients carrying the most common mutation.

30 Sep 2013

Ablynx Nets Another $33.7M From Merck Serono As Partnership Expands

...

27 Sep 2013

Reliable blood flow imaging system developed with inexpensive off-the-shelf commercial parts

Tracking blood flow in the laboratory is an important tool for studying ailments like migraines or strokes and designing new ways to address them. Blood flow is also routinely measured in the clinic, and laser speckle contrast imaging (LSCI) is one way of measuring these changes; however, this technique requires professional-grade imaging equipment, which limits its use.

27 Sep 2013

Targeting cell-division cycle may lead to improved outcomes for patients with medulloblastoma

A new experimental approach to treating a type of brain cancer called medulloblastoma has been developed by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham).

26 Sep 2013

Spanish scientists discover melatonin consumption helps control weight gain

Melatonin is a natural hormone segregated by the body and melatonin levels generally increase in the dark at night. It is also found in fruit and vegetables like mustard, Goji berries, almonds, sunflower seeds, cardamom, fennel, coriander and cherries.

26 Sep 2013

Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

Lpath, Inc., the industry leader in lipidomics-based therapeutics, announced receipt of a Notice of Grant Award from the National Institutes of Health (NIH). This $145,000 Phase 1 SBIR grant will support the study of Lpath's therapeutic monoclonal antibody, Lpathomab™, in animal models of diabetic neuropathic pain and diabetic neuropathy.

23 Sep 2013

MIT researchers develop microfluidic device that mimics flow of cancer cells through blood vessels

Cancer cells metastasize in several stages -- first by invading surrounding tissue, then by infiltrating and spreading via the circulatory system. Some circulating cells work their way out of the vascular network, eventually forming a secondary tumor.

21 Sep 2013

World’s first preclinical Magnetic Particle Imaging (MPI) system announced by Bruker

At the 2013 World Molecular Imaging Congress (WMIC, www.wmicmeeting.org), Bruker today announced the world’s first Magnetic Particle Imaging (MPI) system, an entirely new technology for preclinical imaging. The addition of MPI as a complementary preclinical imaging technique for disease studies, translational research and drug discovery, has significant potential in helping researchers gain new insights into disease processes at the organ, cellular and molecular level.

From Bruker BioSpin Group 19 Sep 2013

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.

19 Sep 2013

New optical imaging tool enables scientists to observe tumors and uncover inner workings

Scientists seeking new ways to fight cancer often try to understand the subtle, often invisible, changes to DNA, proteins, cells, and tissue that alter the body's normal biology and cause disease.

18 Sep 2013

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

18 Sep 2013

Functional brain mapping and high speed physiology multiphoton system from Olympus

The Olympus FluoView® FVMPE-RS, a dedicated multiphoton microscope system, enables high-precision, ultra-fast scanning and stimulation, allowing researchers to see deep within specimens, take measurements at the highest speeds, and capture images even when working under the most demanding conditions.

From Evident Corporation - Life Sciences 17 Sep 2013

Prairie Technologies acquired by Bruker

Bruker Corporation today announced that it has acquired Prairie Technologies, Inc. (Prairie), a provider of life science fluorescence microscopy products. The acquisition strengthens Bruker’s position in life science markets, adding to the Bruker Nano Surfaces Division’s existing life science atomic force microscopy (Bio-AFM) systems.

From Bruker Nano Surfaces and Metrology 13 Sep 2013

CardioExcyte 96 for cardiac toxicity profiling and screening introduced by Nanion

Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to heart liability issues such as ventricular arrhythmia, are very costly. In-vivo methods give highly relevant information but are extremely low throughput allowing the analysis of only a handful of compounds.

From Nanion Technologies 13 Sep 2013

High resolution of U‐SPECT/CT system helps perform kinetic analyses of viral spread in vivo

The ability to visualize and analyze the spread of viral infections in primary and metastatic tumors is an essential component in characterizing the therapeutic efficacy of oncolytic viruses.

12 Sep 2013

Wake Forest Baptist conducts $24 million project to accelerate development of new therapies

Whether it's the Ebola virus or Sarin and Ricin, a key to responding to chemical or biological attacks is having effective antidotes at the ready. To accelerate the development of new therapies, Wake Forest Baptist Medical Center's Institute for Regenerative Medicine is leading a unique $24 million federally funded project to develop a "body on a chip" that will be used to develop these countermeasures.

12 Sep 2013

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology.

12 Sep 2013

Exposing young girls to ionizing radiation can raise risk of breast cancer later in life

Exposing young women and girls under the age of 20 to ionizing radiation can substantially raise the risk of their developing breast cancer later in life. Scientists may now know why. A collaborative study, in which Berkeley Lab researchers played a pivotal role, points to increased stem cell self-renewal and subsequent mammary stem cell enrichment as the culprits.

12 Sep 2013

in vivo News and Research

Scientists uncover new approach to develop induced pluripotent stem cells for in vivo disease modeling

Researchers develop new approach to combat tubercle bacillus

Scientists discover two new compounds that could help treat CF patients having common mutation

Ablynx Nets Another $33.7M From Merck Serono As Partnership Expands

Reliable blood flow imaging system developed with inexpensive off-the-shelf commercial parts

Targeting cell-division cycle may lead to improved outcomes for patients with medulloblastoma

Spanish scientists discover melatonin consumption helps control weight gain

Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

MIT researchers develop microfluidic device that mimics flow of cancer cells through blood vessels

World’s first preclinical Magnetic Particle Imaging (MPI) system announced by Bruker

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

New optical imaging tool enables scientists to observe tumors and uncover inner workings

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

Functional brain mapping and high speed physiology multiphoton system from Olympus

Prairie Technologies acquired by Bruker

CardioExcyte 96 for cardiac toxicity profiling and screening introduced by Nanion

High resolution of U‐SPECT/CT system helps perform kinetic analyses of viral spread in vivo

Wake Forest Baptist conducts $24 million project to accelerate development of new therapies

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

Exposing young girls to ionizing radiation can raise risk of breast cancer later in life

eBook: Using iPSCs models for human disease research and drug discovery eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News